The Statens Serum Institut (SSI) and IAVI shared topline results of the Phase IIb trial of H56:IC31, a subunit TB vaccine developed by SSI. The first analyses of data showed that the vaccine candidate was well tolerated and demonstrated immunogenicity but did not provide protection against TB recurrence. Based on these trial data, SSI has stopped development of the vaccine.
Treatment Action Group (TAG) and the Global TB Community Advisory Board (TB CAB) issued a statement commending the investigators for sharing results early and openly with a diverse group of key stakeholders, and urging the scientific community and funders to continue efforts to find different options to prevent TB, including vaccines that may help people treated for TB avoid experiencing the disease again.
For more TB news, check out the latest edition of the TB Online Weekly Newsletter (#39, 21 December 2023) with the latest TB advocacy and research updates.
Related HIV and Co-Infections News
-
The Lancet Global Health: Untangling the complex relationship between HIV-exposure and TB in children: A narrative review
-
Research Centre Borstel: Long-term cure rates for multidrug-resistant TB much better than expected
-
Liverpool School of Tropical Medicine: New pooled testing toolkit to help expand TB diagnosis to ‘missed millions’
Get involved
Are you living with HIV/AIDS? Are you part of a community affected by HIV/AIDS and co-infections? Do you work or volunteer in the field? Are you motivated by our cause and interested to support our work?
Subscribe
Stay in the loop and get all the important EATG updates in your inbox with the EATG newsletter. The HIV & co-infections bulletin is your source of handpicked news from the field arriving regularly to your inbox.